Investing Profile

Carlos Solórzano

VCInvestor
Sr. Principal at Section 32
s32.com/team/carlos-solorzanoSan Francisco Bay Area
Photo of Carlos Solórzano, Senior Associate at Section 32

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Deutsche Bank Network
276 CONNECTIONS
University of California, Irvine Network
60 CONNECTIONS
UC Irvine Network
53 CONNECTIONS
University of California, San Francisco Network
37 CONNECTIONS
Oppenheimer & Co. Inc. Network
30 CONNECTIONS
cb
Section 32 Senior Associate
Pivotal bioVenture Partners Sr. Associate
$10K - $50K
$25K
$740M
Sr. Principal Section 322022 - Present
President - Bay Area Chapter Oxbridge Roundtable SolutionsPresent
Equity Research Associate - Biotechnology Oppenheimer & Co.Present
Assoc Director, Corporate Strategy UltragenyxPresent
Sr. Principal S32Present
Investor in residence Ally Bridge GroupPresent
Principal Ally Bridge GroupPresent
Sr. Associate Pivotal Life Sciences2019 - 2022
Sr. Associate Pivotal bioVenture Partners2019 - 2022
Assoc Director, Corporate Strategy Ultragenyx Pharmaceutical Inc.2018 - 2019
Equity Research Associate - Biotechnology Deutsche Bank2016 - 2018
Equity Research Associate - Biotechnology Oppenheimer & Co. Inc.2015 - 2016
NIH Postdoctoral Fellow University of California, San Francisco2010 - 2015
President - Bay Area Chapter Oxbridge Biotech Roundtable2014 - 2014
Keck Graduate Institute Intensive Summer Business Course
University of California, Irvine Ph.D. Pharmacology and Toxicology
California State Polytechnic University-Pomona B.Sc. Chemical Engineering
UC Irvine Ph.D. Pharmacology and Toxicology
Sign in with Google →
Sign in with Google →